AstraZeneca’s asthma drug gets regulator’s approval in China
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
Fifteen member states of the European Union and the European Economic Area will procure up to 40 million doses of avian influenza virus.
HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.
HQ Team April 3, 2024: Humans’ lack of immunity may rapidly result in the transmission of bird flu among people if the avian.
HQ Team December 22, 2023: Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to.
HQ Team October 3, 2023: France has started a vaccination programme for farmed ducks to protect them against highly pathogenic avian influenza (HPAI).
HQ Team September 29, 2023: Pfizer announced the availability of its migraine management drug Rimegepant in Hong Kong — the company’s first market.